- Home
- ARTV vs NPCE Comparison
ARTV vs NPCE Comparison
Compare ARTV & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- NPCE
- Stock Information
- Founded
- ARTV 2019
- NPCE 1997
- Country
- ARTV United States
- NPCE United States
- Employees
- ARTV N/A
- NPCE N/A
- Industry
- ARTV
- NPCE Medical Specialities
- Sector
- ARTV
- NPCE Health Care
- Exchange
- ARTV NYSE
- NPCE Nasdaq
- Market Cap
- ARTV 232.8M
- NPCE 217.5M
- IPO Year
- ARTV 2024
- NPCE 2021
- Fundamental
- Price
- ARTV $11.79
- NPCE $6.94
- Analyst Decision
- ARTV Strong Buy
- NPCE Buy
- Analyst Count
- ARTV 5
- NPCE 7
- Target Price
- ARTV $21.25
- NPCE $16.00
- AVG Volume (30 Days)
- ARTV 79.3K
- NPCE 41.5K
- Earning Date
- ARTV 08-29-2024
- NPCE 11-04-2024
- Dividend Yield
- ARTV N/A
- NPCE N/A
- EPS Growth
- ARTV N/A
- NPCE N/A
- EPS
- ARTV N/A
- NPCE N/A
- Revenue
- ARTV $29,256,000.00
- NPCE $71,819,000.00
- Revenue This Year
- ARTV N/A
- NPCE $20.21
- Revenue Next Year
- ARTV N/A
- NPCE $15.04
- P/E Ratio
- ARTV N/A
- NPCE N/A
- Revenue Growth
- ARTV 493.31
- NPCE 30.75
- 52 Week Low
- ARTV $9.71
- NPCE $5.75
- 52 Week High
- ARTV $16.00
- NPCE $18.15
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- NPCE 47.37
- Support Level
- ARTV N/A
- NPCE $6.69
- Resistance Level
- ARTV N/A
- NPCE $7.23
- Average True Range (ATR)
- ARTV 0.00
- NPCE 0.48
- MACD
- ARTV 0.00
- NPCE -0.04
- Stochastic Oscillator
- ARTV 0.00
- NPCE 29.29
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.